Skip to Main Content

Paper Details

Case Report: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous heteroplasia.
Front Pediatr
0
2022
Author NameAffiliation
Irene Rivero-CalleHealth Research Institute of Santiago de Compostela (IDIS)
Irene Rivero-CalleHospital Clinico Universitario de Santiago de Compostela
Jacobo Pardo-SecoHealth Research Institute of Santiago de Compostela (IDIS)
Jacobo Pardo-SecoHospital Clinico Universitario de Santiago de Compostela
Alberto G??mez-CarballaHealth Research Institute of Santiago de Compostela (IDIS)
Alberto G??mez-CarballaHospital Clinico Universitario de Santiago de Compostela
Federico Martin??n-TorresHealth Research Institute of Santiago de Compostela (IDIS)
Federico Martin??n-TorresHospital Clinico Universitario de Santiago de Compostela
  • 1 - 8

Datasets

Release 1.2